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Abstract 
We assessed the ability of pre-operative B-type natriuretic peptide (BNP) levels to predict 
medium-term mortality in patients undergoing major noncardiac surgery. During a median 
654 days follow-up 33 patients from a total cohort of 204 patients (16%) died. The optimal 
cut-off in this cohort, determined using a receiver operating characteristic curve, was 
>35pg.mL-1. This was associated with a 3.47-fold increase in the hazard of death (p=0.001) 
and had a sensitivity of 70% and a specificity of 68% for this outcome. These findings 
extend recent work demonstrating that BNP levels obtained before major noncardiac 
surgery can be used to predict peri-operative morbidity, and indicate that they also forecast 
medium-term mortality. 
 
Introduction 
Major non-cardiac surgery is associated with a high risk of early cardiovascular 
complications.1 In addition, there is a significant longer-term mortality in these patients. 
Some of these late deaths may relate to the underlying pathology, but many are due to 
cardiovascular disease. Peri-operative and early post-operative cardiac events predict an 
excess medium term mortality.2, 3 In particular, even small elevations in markers of 
myocardial cell necrosis, such as cardiac troponin I (cTnI) or T, are associated with an 
increased risk of death.2, 3  Recently, several relatively small studies have also 
demonstrated that pre-operative levels of B-type natriuretic peptide (BNP) and N-
terminal pro-BNP are useful predictors of peri-operative cardiac complications in this 
setting.4-8 These studies have, however, largely relied on subjective, short-term, end-
points. The aim of the current study is therefore, to determine the usefulness of pre-
operative BNP in predicting longer-term mortality after major non-cardiac surgery, and to 
 3
- 4 - 
   AJC-D-07-00498 
assess whether such measures provide any additional prognostic information to that 
afforded by post-operative troponin levels.
 
Methods 
The study was approved by the local ethics committee and written informed consent was 
obtained. Consecutive patients undergoing scheduled major non-cardiac surgery were recruited. 
This included patients undergoing major vascular surgery, major gastrointestinal surgery and 
major pelvic cancer surgery. Patients requiring emergency or minor surgery were excluded. Pre-
operative data collection included patient demographics, medical and drug history. In addition, 
the Revised Cardiac Risk Index9 was calculated. Pre-operative blood samples were obtained for 
Cardiac Troponin (cTnI) and BNP and details of surgery and anesthesia were also recorded. Post 
operative data collection included the recording of a 12 lead Electrocardiograph (ECG) and 
measurement of cTnI at 24 and 72 hours after surgery. Patients were followed-up while in 
hospital and subsequent vital status determined using data provided by the General Register 
Office for Scotland. The primary endpoint was all-cause mortality. BNP and cTnI assays were 
measured using the Bayer ADVIA Centaur™ immunoassay. The lower limit of detection for 
BNP is 5pg.ml-1 and the coefficients of variation at 48pg.ml-1 and 461pg.ml-1 are 3.4% and 2.9% 
respectively.10 The 99th percentile value for the cTnI assay is 0.16µg/L with a coefficient of 
variation of <10% achieved at levels ≥0.32µg/L.11
 
Categorical data are summarised using absolute values (percentage). Normally distributed 
continuous data are presented as mean (standard deviation) or, where skewed, as median 
(interquartile range). Long-term survival was described using the Kaplan-Meier method and 
comparisons made using the log-rank statistic. Estimations of risk were performed using Cox 
regression. All univariable predictors were then entered in a stepwise manner into a multivariable 
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model of survival, with entry and retention set at a significance level of <0.05. A receiver 
operating characteristic (ROC) curve, assessing the ability of pre-operative BNP to predict 
mortality, was plotted and the area under the curve (with 95% confidence interval) estimated. A 
p-value <0.05 was considered significant. 
 
Results 
From September 2004 to April 2005, 239 patients eligible to take part in the study were 
invited to participate. Twenty (8%) refused consent. It was not possible to obtain pre-operative 
blood samples from 5 patients (2%) and 10 (4%) patients did not undergo major surgery and were 
excluded. The remaining 204 patients completed the trial protocol. Baseline characteristics for 
this cohort are shown in table 1. Seventy (34%) patients underwent major vascular surgery, 84 
(41%) major abdominal surgery and 50 (25%) major pelvic surgery. The utility of pre-operative 
BNP levels in predicting early cardiac events in this cohort has been previously reported.8
 
Vital status data were available for all study participants. One patient (0.5%) died within 
30 days of surgery. During a median 654 (interquartile range 532-711) days follow-up 33 patients 
(16%) died. Seventeen (24%) died after major vascular surgery, 9 (11%) after major abdominal 
surgery and 6 (12%) after major pelvic surgery. No patients had detectable (>0.10µg/L) cTnI 
levels pre-operatively. In contrast, post-operative cTnI levels >0.10µg/L at 24 and/or 72 hours 
were observed in 12 out of 70 (17%) patients undergoing major vascular surgery and 15 out of 
130 (12%) of those undergoing major abdominal/pelvic surgery. Elevated cTnI levels 24 hours 
after surgery were powerful predictors of long-term mortality. In contrast, cTnI levels at 72 hours 
were not significant predictors. 
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When analyzed as a continuous variable, pre-operative BNP levels did not predict long-
term outcome. The relationship between BNP and subsequent death was not, however, linear – 
with the excess hazard primarily associated with a pre-operative BNP level in the upper quartile 
(table 1 and figure 1). In this cohort a ROC curve identified the optimal cut-off level of BNP for 
long-term mortality as 35pg.mL-1, which achieved a sensitivity of 70% and a specificity of 68%. 
The area under the ROC curve was 0.70 (95% CI 0.61-0.79, p<0.001). Figure 2 shows the Kaplan 
Meier curve demonstrating survival in patients with BNP levels below and above this threshold. 
 
To assess whether BNP levels conveyed independent prognostic information regression 
models were developed. In the first of these BNP dichotomised around the optimal cut-off level 
of 35pg.mL-1 was entered along with cTnI levels at 24 hours post-operatively. This demonstrated 
that, even after correction for cTnI levels, BNP levels >35pg.mL-1 remained strong predictors of 
subsequent death (HR 3.17, 95% CI 1.48-6.79, p=0.003). A further backward conditional model 
was developed including BNP levels >35pg.mL-1, cTnI levels at 24 hours post-operatively, age 
and the Revised Cardiac Risk Index. In this model the only independent predictor of death was 
age (HR 1.48 per 10 year increase, 95% CI 1.04-2.12, p=0.03). However, there was a trend 
towards BNP levels >35pg.mL-1 independently predicting outcome (HR 2.25, 95% CI 0.97-5.25, 
p=0.06). 
 
Discussion 
The current study confirms that elevated pre-operative BNP levels in patients undergoing 
non-cardiac surgery are associated with an increased risk of mortality during medium-term 
follow-up. These results extend the findings from several recent small studies that have 
demonstrated that BNP levels may be used to predict an increased risk of peri-operative adverse 
events in this setting.4-8 In addition, the current data suggest that BNP may provide prognostic 
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information that is incremental to that obtained from post-operative cardiac troponin levels. It has 
already been suggested that pre-operative BNP and/or levels might assist in differentiating 
patients who have a very low-risk of peri-operative cardiac events from those who require more 
detailed cardiovascular testing and optimization of therapy prior to major non-cardiac surgery.5 
The current data suggest this that this strategy might result in improved long-term outcome. This, 
however, requires to be tested prospectively. 
 
The Revised Cardiac Risk Index9 did not prove to be a useful measure of medium-term 
outcome in this cohort. This most likely reflects the relative homogeneity of the current cohort in 
terms of their clinical risk scores. Likewise, the Revised Cardiac Risk Index was developed to 
predict peri-operative events - including clinically defined measures of morbidity, some using 
outdated definitions - and not long-term mortality. It was also derived and validated in patients 
≥50 years old. In addition to its superior prognostic performance in this cohort, BNP levels have 
several other advantages. Measurement relies on a relatively cheap and widely available blood 
test. A biochemical test also avoids the difficulties inherent in applying complex scoring systems 
and provides an objective measure without the potential for subjective interpretation.  
 
The current study confirms that, among patients undergoing major non-cardiac surgery, 
cardiac troponin levels are frequently elevated after surgery, even in patients who are undergoing 
non-vascular surgery. It also demonstrates that patients exhibiting only minor elevations have a 
higher medium-term mortality. 
 
This was a small study of patients undergoing diverse major surgical procedures. Ideally, 
these results should be verified in a study powered to detect hospital and longer-term mortality in 
all surgical subgroups. Use of all-cause mortality has the advantage of being entirely objective. 
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 We acknowledge, however, that data relating to the cause of death and other non-fatal 
outcomes would have been of interest. Further work should determine the utility of BNP in 
combination with existing risk stratification tools and, more importantly, assess whether 
interventions that reduce BNP levels can prevent peri-operative and longer-term complications. 
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Table 1. Baseline patient characteristics. 
 
Patient characteristic Total cohort (n=204) 
Died during 
follow-up 
(n=33) 
Survivors at time of 
follow-up 
(n=171) 
Hazard ratio 
(95% CI) 
P 
value 
Men 125 (61%) 21 (63%) 104 (61%) 1.04 (0.51-2.12) 0.91 
Age (years) 66 (57-74) 74 (68-80) 64 (57-72) 1.06 (1.03-1.09) <0.001
Cardiac medication† 108 (53%) 20 (60%) 88 (52%) 1.13 (0.55-2.31) 0.74 
Diabetes mellitus 30 (15%) 6 (18%) 24 (14%) 1.17 (0.48-2.83) 0.74 
Hypertension 74 (36%) 15 (45%) 59 (35%) 1.45 (0.73-2.87) 0.29 
Prior myocardial infarction 20 (10%) 2 (6%) 18 (10%) 0.40 (0.09-1.69) 0.21 
Prior angina pectoris 47 (23%) 10 (30%) 37 (22%) 1.02 (0.47-2.24) 0.96 
Prior atrial fibrillation 7 (3%) 1 (3%) 6 (3%) 0.93 (0.13-6.83) 0.94 
Current smoker 48 (23%) 10 (30%) 38 (22%) 1.36 (0.64-2.86) 0.41 
Prior revascularization 12 (6%) 1 (3%) 11 (6%) 0.44 (0.06-3.23) 0.42 
Creatinine (µmol.ml-1) 92 (82-106) 96 (85-107) 92 (82-106) 1.00 (0.99-1.02) 0.78 
Revised Cardiac Risk Index ≥2 65 (32%) 14 (42%) 19 (11%) 1.37 (0.67-2.79) 0.38 
Post-operative ECG changes 14 (7%) 1 (3%) 13 (8%) 0.34 (0.05-2.51) 0.29 
cTnI at 24 hours (µg.L-1) 0.03 ±0.15 0.10 ±0.29 0.02 ±0.11 4.84 (1.51-15.57) 0.008 
cTnI at 72 hours (µg.L-1) 0.09 ±0.67 0.13 ±0.40 0.08 ±0.72 0.96 (0.65-1.41) 0.84 
cTnI >0.10µg.L-1 at 24 +/or 72 hours 27 (13) 9 (27) 18 (11) 2.18 (1.00-4.73) 0.05 
Pre-operative BNP (pg/mL-1) 26.6 (11.5-50.3) 50.4 (24.8-76.1) 21.5 (10.1-45.5) 1.02 (0.97-1.06) 0.50 
Quartiles of BNP (pg/mL-1      
     Quartile 1 (0-11.4) 51 (25%) 3 (9) 48 (28) 1 - 
     Quartile 2 (11.5-26.4) 51 (25%) 5 (15) 46 (27) 1.66 (0.40-6.96) 0.49 
     Quartile 3 (26.5-49.9) 51 (25%) 8 (24) 43 (25) 2.59 (0.69-9.78) 0.16 
     Quartile 4 (50.0-376.0) 51 (25%) 17 (52) 34 (20) 4.92 (1.43-16.94) 0.01 
Pre-operative BNP >35pg.mL-1 78 (38%) 23 (70) 55 (32) 3.47 (1.64-7.34) 0.001 
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† Cardiac medication is defined as the regular prescription of a medication for a cardiovascular disease; ║ 
Optimal cut-off as defined by receiver operating characteristic curve; MI = myocardial infarction, BNP = 
B-type natriuretic peptide. 
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Figure 1. Quartiles of pre-operative BNP and subsequent mortality. 
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Figure 2. Pre-operative BNP levels >35pg.mL-1 and subsequent mortality. 
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